Home | Contact | Employees | Incident Reporting | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Jul 21, 2021 Santen to Present Latest Data on STN2000100 at 2021 ASCRS Annual Meeting
Jul 21, 2021 Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Jul 8, 2021 Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative
Jun 28, 2021 Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Jun 24, 2021 Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
Jun 24, 2021 Santen to Present Latest Data on STN2000100 at COS 2021 and 9th WGC
Jun 3, 2021 Santen to Present Latest Data on Omidenepag Isopropyl at APGC 2021
May 19, 2021 Santen Announces Medium-Term Plan "MTP2025"
May 19, 2021 Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
May 18, 2021 Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets
May 17, 2021 Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equality and women's empowerment in the workplace, marketplace and community
May 11, 2021 Notice of Postponement of "Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year"
May 11, 2021 Notice of Board of Director and Corporate Auditor Nominations
May 11, 2021 Santen Reports Fiscal 2020 Consolidated Performance
May 11, 2021 Santen Reports Fiscal 2020 Consolidated Performance
May 11, 2021 Notice of Postponement of Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year
Apr 22, 2021 Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-
Apr 9, 2021 Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 9, 2021 Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 6, 2021 Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Mar 22, 2021 Notice of Corporate Officer Appointments
Mar 12, 2021 Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year
Mar 12, 2021 Santen Recognized as One of Outstanding Enterprises in 2021 Certified Health and Productivity Management Outstanding Organization (Large Enterprise Category)
Feb 5, 2021 Santen and IAPB Partner to Advocate for Better Eye Health
Feb 4, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Feb 4, 2021 Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year
Feb 4, 2021 (Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
Feb 4, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Feb 2, 2021 Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Feb 1, 2021 Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Jan 8, 2021 Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Jan 8, 2021 Corporate Social Responsibility (CSR) page on our website has been updated
Jan 7, 2021 Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities

Working at Advanced Vision Science

Working at Advanced Vision Science